Read Gene

Read Gene Change in Working Capital

The Change in Working Capital of Read Gene (RDG.WA) as of Nov 18, 2026 is -1.08 M PLN. In the previous year, Change in Working Capital was 2.23 M PLN — a change of -148.52% (lower).

Change in Working Capital

-1.08 MPLN

YoY

-148.52%

Last updated:

Change in Working Capital of Read Gene is 2025 -1.08 M PLN. Change in Working Capital of Read Gene was 2024 2.23 M PLN. It decreases by -148.52% lower compared to the previous year.

The Read Gene Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-643,140.00 PLN
Jan 1, 2019
-1.24 M PLN
Jan 1, 2020
-46,290.00 PLN
Jan 1, 2021
-1.56 M PLN
Jan 1, 2022
-669,147.80 PLN
Jan 1, 2023
-512,218.60 PLN
Jan 1, 2024
2.23 M PLN
Jan 1, 2025
-1.08 M PLN
The Read Gene Change in Working Capital history
YEARChange in Working CapitalYoY
-1.08 MPLN-148.52%
2.23 MPLN-534.88%
-512,218.60PLN-23.45%
-669,147.80PLN-57.19%
-1.56 MPLN+3,276.56%
-46,290.00PLN-96.25%
-1.24 MPLN+92.06%
-643,140.00PLN-158.66%
1.10 MPLN-3,546.81%
-31,810.00PLN-98.16%
-1.73 MPLN-149.07%
3.53 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Change in Working Capital of Read Gene is -1.08 M PLN in 2025.

Change in Working Capital of Read Gene changed from 2.23 M PLN to -1.08 M PLN, representing a -148.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Read Gene since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Read Gene

All Key Metrics — Read Gene